OBJECTIVES: To refine a previously published standardized quality and utilization measurement set for migraine care and to establish performance benchmarks. STUDY DESIGN: Retrospective application of the migraine measurement set to health plan data in order to assess patterns of health service utilization. METHODS: Measurement specifications were applied to data from 10 health plans for measurement year 2009. RESULTS: Of the 2.9 million continuously enrolled members of the health plans, 138,004 (4.7%) met inclusion criteria for the migraine population. Of these, 26% did not have a migraine diagnosis, but were utilizing migraine drugs; 12% had a computed tomography scan within the year (range 8%-25% across plans); and 8% had magnetic resonance imaging (range 6%-11%). Nearly 18% of the migraineurs had 1 or more visits to an emergency department/urgent care center for migraine; few (6%) were followed up with primary care visits. Approximately one-fourth of the migraineurs were not being routinely monitored by a physician. Medication utilization also was examined for members of the migraine population with pharmacy benefits. A significant proportion (42%) were given a migraine preventive, 38% had at least 1 prescription for a triptan, and 2% of those on triptans were potentially overutilizing the medication. Among patients aged 18 to 49 years who were given triptans, 3% had a cardiac contraindication; this percentage rose to 7% for patients aged 50 to 64 years. CONCLUSIONS: This study demonstrates the value of standardized measures in identifying potential quality issues for migraine care, including underdiagnosis, overutilization of imaging, and underutilization of preventive drugs.
OBJECTIVES: To refine a previously published standardized quality and utilization measurement set for migraine care and to establish performance benchmarks. STUDY DESIGN: Retrospective application of the migraine measurement set to health plan data in order to assess patterns of health service utilization. METHODS: Measurement specifications were applied to data from 10 health plans for measurement year 2009. RESULTS: Of the 2.9 million continuously enrolled members of the health plans, 138,004 (4.7%) met inclusion criteria for the migraine population. Of these, 26% did not have a migraine diagnosis, but were utilizing migraine drugs; 12% had a computed tomography scan within the year (range 8%-25% across plans); and 8% had magnetic resonance imaging (range 6%-11%). Nearly 18% of the migraineurs had 1 or more visits to an emergency department/urgent care center for migraine; few (6%) were followed up with primary care visits. Approximately one-fourth of the migraineurs were not being routinely monitored by a physician. Medication utilization also was examined for members of the migraine population with pharmacy benefits. A significant proportion (42%) were given a migraine preventive, 38% had at least 1 prescription for a triptan, and 2% of those on triptans were potentially overutilizing the medication. Among patients aged 18 to 49 years who were given triptans, 3% had a cardiac contraindication; this percentage rose to 7% for patients aged 50 to 64 years. CONCLUSIONS: This study demonstrates the value of standardized measures in identifying potential quality issues for migraine care, including underdiagnosis, overutilization of imaging, and underutilization of preventive drugs.
Authors: Stephen Ross; Eric Wall; Becky Schierman; J Mark Bailey; Eric Cheng; Charles Flippen; Shannon Petersen; Amy Sanders; David Seidenwurm; M Cristina Victorio Journal: Neurology Date: 2015-01-13 Impact factor: 9.910
Authors: Richard B Lipton; Daniel Serrano; Dawn C Buse; Jelena M Pavlovic; Andrew M Blumenfeld; David W Dodick; Sheena K Aurora; Werner J Becker; Hans-Christoph Diener; Shuu-Jiun Wang; Maurice B Vincent; Nada A Hindiyeh; Amaal J Starling; Patrick J Gillard; Sepideh F Varon; Michael L Reed Journal: Cephalalgia Date: 2015-05-22 Impact factor: 6.292
Authors: Sean C Blackwell; Erin M Sullivan; Allison A Petrilla; Xian Shen; Kathleen A Troeger; James D Byrne Journal: Clinicoecon Outcomes Res Date: 2017-10-03